| Document |
Document Title |
|
JP2010540612A |
The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, X4, X5, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them a...
|
|
JP2010280701A |
To provide a pharmaceutical formulation for administration by inhalation having a therapeutically useful effect in the treatment of inflammatory disorders of the respiratory tract.The pharmaceutical formulation containing a compound of f...
|
|
JP4598268B2 |
The invention provides sterile glucocorticosteroids and sterile formulations containing glucocorticosteroid and use thereof in the treatment of an allergic and/or inflammatory condition of the nose or the lungs.
|
|
JP2010273593A |
To provide tomato powder having a high nutritive value essential to tomato, an excellent physiological activity action and is easily taken, and to provide a method for producing the same and the use thereof.The dried edible tomato powder...
|
|
JP4573157B2 |
The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and derivatives thereof, in the treatment of non- cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor- senso...
|
|
JP4541698B2 |
3-Hydroxy-7-hydroxy steroids and 3-oxo-7-hydroxy steroids, especially the 7β-isomers thereof, and pharmaceutically acceptable esters thereof are useful for protection against ischaemia-induced damage to peripheral organs, such as the he...
|
|
JP4537652B2 |
A medicament (A) comprises a combination of anticholinergic agent(s) (I) and the corticosteroid ST-126 (II), optionally together with pharmaceutical auxiliaries. ACTIVITY : Antiinflammatory; Antiasthmatic; Antiallergic. MECHANISM OF ACTI...
|
|
JP4508651B2 |
There is provided a crystalline complex comprising a compound of formula (I) in which the crystal lattice is stabilized by the presence of a guest molecule, characterized in that the crystalline complex is of space group P212121 having u...
|
|
JP2010522233A |
The present invention relates to certain unsaturated fatty acid derivatives of therapeutically active glucocorticoides-fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents and pharmaceutical formulations conta...
|
|
JP4481831B2 |
An improved stereoselective process for the preparation of 6alpha-fluoropregnane derivatives of formula (I), comprising the reaction of 3-benzoyloxy Delta3,5-pregnane derivatives of formula (II), with an electrophilic fluorination agent ...
|
|
JP4474101B2 |
The present invention relates to novel compounds represented by the structure I and pharmaceutical preparations thereof for the treatment of inflammatory diseases in humans and animals.
|
|
JP2010515777A |
The present invention provides a purification method for air sensitive steroids, by reacting an amino acid or an analogue thereof with the 21-aldehyde oxidation product of such air sensitive steroids to form an adduct that is separated f...
|
|
JP2010513325A |
A pharmaceutical composition comprising eplerenone having a D90 particle size of between 15-25 microns and further comprising one or more pharmaceutically acceptable excipients.
|
|
JP2010513252A |
Producing steroidal amines (I) with an alpha or beta primary amino group in position 1, 2, 3, 4, 6, 7, 11, 12, 15, 16 or 17 comprises treating the corresponding oxime (II) with lithium in liquid ammonia at -33 to -90[deg] C in a solvent ...
|
|
JP4456811B2 |
The invention relates to a process for the preparation of 16,17-[(cyclohexylmethylene)bis(oxy)]-11,21-dihydroxypregna-
1,4-diene-3,20-dione[11beta,16alpha(R)] and similar compounds, by reaction of an appropriate 16,17-ketal with cyclohex...
|
|
JP4450435B2 |
The invention relates to a method of alleviating the symptoms of PMS and anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor...
|
|
JP2010510309A |
As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disord...
|
|
JP2010070567A |
To provide a method for sterilizing a powdery form glucocorticosteroid, sterile glucocorticosteroid, sterile formulation containing glucocorticosteroid, and use thereof for treating an allergic and/or inflammatory condition of the nose o...
|
|
JP4437923B2 |
A process for a preparation of Compound (V), a pharmaceutically acceptable salt or a solvate thereof, said process comprising the steps represented by the following formula: wherein R<1> and R<2> are each independently C1 - C8 alkyl
|
|
JP2010504921A |
The invention relates to a method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, wherein the water-insoluble terpenoid having a free carboxylic, hydroxy or amino functional group is der...
|
|
JP2010031034A |
To provide a method of treatment, sapogenin, related compounds and their derivatives.There is disclosed a method of treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration, ...
|
|
JP2010503722A |
The present invention relates to crystalline ciclesonide methanol solvate Form C, processes for its preparation, its use in the synthesis of crystalline ciclesonide Form A and its use in medicine.
|
|
JP2010018563A |
To specify a compound existing in the fruit body of Grifola gargal and exhibiting an osteoclastogenesis suppressing effect and to provide a prophylactic or therapeutic agent for bone diseases, comprising the compound.The prophylactic or ...
|
|
JP4382735B2 |
The present invention provides a therapeutic agent for neuropathic pain having an excellent treating effect on neuropathic pain, which is an intractable disorder. More specifically, the present invention provides a therapeutic agent for ...
|
|
JP4368945B2 |
The invention relates to compounds of the formula : wherein : R1, R2, R3, R4 and R6 each independently represent hydrogen or a (C1-C6)alkyl, R5 is hydrogen, a (C1-C6)alkyl or a group -COR7 where R7 is a (C1-C6)alkyl, n is zero or one, an...
|
|
JP2009215317A |
To provide a sulfatase inhibitor which needs a compound limiting or preventing the usage of estrogen in hormone-dependent tumor, and does not have an estrogenic active component.The invention relates to a new estratriene expressed by gen...
|
|
JP2009209099A |
To provide a prophylactic and therapeutic agent for arteriosclerosis, a blood cholesterol-lowering agent and a macrophage foaming inhibitor by identifying a substance that inhibits macrophage foaming, lowers blood cholesterol and prevent...
|
|
JP4331478B2 |
The invention relates to a process for the production of 4-(17alpha-methyl-substituted 3-oxoestra-4,9-dien-11beta-yl)benzaldehyde-(1E or 1Z)-oximes of general formula (I), in which R1 is a hydrogen atom, a C1-6-alkyl radical or a CnF2n+1...
|
|
JP4326696B2 |
The invention provides the use of a glucocorticoid having a first pass metabolism in the liver of at least 90 % as active substance, for the manufacturing of a medicament for oral or rectal administration in the treatment of glomerulonep...
|
|
JP2009530405A |
The present invention comprises small molecule inhibitors of cell proliferative conditions, in particular cancer and conditions associated with cancer. For example, associated malignancies include ovarian cancer, cervical cancer, breast ...
|
|
JP2009179630A |
To inhibit angiogenesis and treat or prevent unwanted cell proliferation including tumors.A composition and a method inhibit the hedgehog pathway with the use of an antagonist of the hedgehog pathway and, for example, the hedgehog antago...
|
|
JP2009167188A |
To provide a new compound having a specific strong progesterone-like property and devoid of residual androgenic activity.The compound is expressed by formula (I), wherein R1, R2, R3, R4, R5 and R6 are each a hydrogen atom or a specific s...
|
|
JP2009526858A |
The present invention relates to methods of manufacturing compositions comprising a corticosteriod and at least one solubility enhancer, as well as compositions made by these methods.
|
|
JP2009526068A |
The invention encompasses a crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 1 1.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta ± 0.2 degrees two-theta, methods of its preparation and pharmaceutical...
|
|
JP2009523140A |
The present patent application relates to the use of triazine derivatives as cicatrising or angiogenic agents.
|
|
JP4267448B2 |
The present invention relates to the chemical synthesis of solanum glycosides, in particular to the synthesis of solamargine as well as to novel beta-monosaccharide Intermediate compounds.
|
|
JP4269110B2 |
The invention provides an improved process for the preparation of 17-esters of 9 alpha ,21-dihalo-pregnane-11 beta ,17 alpha -diol-20-ones, and in particular for the preparation of 17-esters of anti-inflammatory steroids according to the...
|
|
JP4263478B2 |
The invention relates to a method for the production of 4-(17alpha substituted 3-oxoestra-4,9-dien-11beta-yl)benzaldehyd-(1E or 1Z)-oximes of general formula (I), where R1-H, C1-6 alkyl or a CnF2n+1 group; R2-C1-4 alkyl, X=E- or Z-OH; an...
|
|
JP4260886B2 |
A compound having the general formula: in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH3 and —CHOHCH3; R2 is a member selected from the group consisting of halogen, ...
|
|
JP2009513527A |
The invention pertains to steroid modified solatrioses and the synthesis thereof as well as to intermediate compounds useful for the synthesis of the steroid modified solatrioses.
|
|
JP2009513526A |
The present invention relates to steroid modified chacotrioses and the synthesis thereof as well as to intermediate compounds useful for the synthesis of the steroid modified chacotrioses and solatrioses. Moreover, the present inventions...
|
|
JP2009512733A |
Provided is a process for increasing the 22R/22S epidemic ratio of ciclesonide.
|
|
JP4222810B2 |
|
|
JP4219105B2 |
A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided compr...
|
|
JP2009500386A |
Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc - T are provided using compounds of the formula I wherein R 1 is H, -OH, C 1-6 alkoxy, -NR 5 R 6 , or Sac 1; R 2 is H, -OH, C 1-6 alkoxy or Sac 2; R 3 i...
|
|
JP2009500385A |
A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T is provided, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-...
|
|
JP2008546694A |
A mutual prodrug of a corticosteroid and a substituted phenylphosphate (β-agonist derivative) for formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is p...
|
|
JP2008542214A |
The present invention relates to pharmaceutical compositions and combinations for treating cancer, comprising a diaryl urea compound e.g. 4 {4- [3- (4-chloro-3-trifluoromethylphenyl) -ureido] -3-fluorophenoxy}-pyridine-2- carboxylis acid...
|
|
JP4173719B2 |
|
|
JP2008214356A |
To prevent angiogenesis and to cure or prevent undesirable cell proliferation including a tumor.The invention relates to a composition and a method for inhibiting a hedgehog route by using an antagonist for the hedgehog route, for exampl...
|
